Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Acquired by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP increased its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 965.2% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 127,161 shares of the company's stock after acquiring an additional 115,223 shares during the period. ExodusPoint Capital Management LP owned approximately 0.18% of Kiniksa Pharmaceuticals worth $2,515,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. FMR LLC grew its holdings in shares of Kiniksa Pharmaceuticals by 36,925.0% during the 3rd quarter. FMR LLC now owns 696,810 shares of the company's stock worth $17,413,000 after purchasing an additional 694,928 shares during the period. Jane Street Group LLC lifted its position in Kiniksa Pharmaceuticals by 1,064.4% in the third quarter. Jane Street Group LLC now owns 345,092 shares of the company's stock valued at $8,624,000 after buying an additional 315,456 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Kiniksa Pharmaceuticals by 138.9% during the fourth quarter. JPMorgan Chase & Co. now owns 477,800 shares of the company's stock worth $9,451,000 after buying an additional 277,827 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals during the fourth quarter valued at about $3,955,000. Finally, Globeflex Capital L P increased its position in shares of Kiniksa Pharmaceuticals by 217.1% during the fourth quarter. Globeflex Capital L P now owns 88,596 shares of the company's stock valued at $1,752,000 after acquiring an additional 60,656 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on KNSA shares. Citigroup began coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They set a "buy" rating and a $40.00 price objective for the company. Wedbush reaffirmed an "outperform" rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $37.17.

Insider Activity

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 14,000 shares of the firm's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $19.57, for a total value of $273,980.00. Following the sale, the chief operating officer now directly owns 81,975 shares in the company, valued at $1,604,250.75. This trade represents a 14.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Michael R. Megna sold 9,051 shares of Kiniksa Pharmaceuticals stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total value of $203,194.95. Following the sale, the chief accounting officer now directly owns 26,528 shares of the company's stock, valued at $595,553.60. This trade represents a 25.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 93,766 shares of company stock worth $2,011,735. 54.57% of the stock is currently owned by company insiders.

Kiniksa Pharmaceuticals Stock Up 3.5 %

Kiniksa Pharmaceuticals stock traded up $0.66 during mid-day trading on Friday, reaching $19.31. 692,369 shares of the company's stock were exchanged, compared to its average volume of 458,499. The company has a fifty day moving average of $20.97 and a 200-day moving average of $21.62. The company has a market cap of $1.40 billion, a P/E ratio of -137.92 and a beta of 0.31. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $16.56 and a twelve month high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company had revenue of $122.50 million during the quarter, compared to analysts' expectations of $123.42 million. During the same quarter last year, the business posted $0.35 earnings per share. The company's revenue for the quarter was up 46.9% on a year-over-year basis. Equities research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.